| NCT05092360 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease) | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) | AL, AK, AZ, CA, FL, IL, IN, KY, LA, MD, MI, NJ, NM, NY, NC, OH, OR, PA, SD, TX, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | MI, TX, UT, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05824975 | I/IIa | Advanced solid tumors | An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid Tumors | AZ, FL, MN, OH | View Drugs | |
GI-102 | bispecific CD80-lgG4Fc-IL-2v fusion protein GI-102 | Blocks CTLA-4 interaction with its ligand CD80 and activates IL-2R beta/gamma to increase T cell activation and immune response | Clinical Trials |
|
|
| NCT04977453 | I/II | Advanced solid tumors | A Phase 1/2 Study to Evaluate Safety, Tolerability, PK, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced, Metastatic Solid Tumors | NY, NC | View Drugs | View Results |
GI-101 | bispecific CD80-lgG4Fc-IL-2v fusion protein GI-101 | Blocks CTLA-4 interaction with its ligand CD80 and activates IL-2R beta/gamma to increase T cell activation and immune response | Clinical Trials | Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT04009681 | I/II | Advanced solid tumors | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | AZ, CO, FL, TN, TX | View Drugs | View Results |
anti-EGFR Ab | | EGFR antagonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | SAR444245 | pegylated recombinant IL-2 variant THOR-707, THOR-707 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials |
|
|
| NCT05081609 | I/II | Advanced solid tumors | IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | MA, NC, OH, PA, TN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | TransCon IL-2 β/γ | | IL-2R/IL-15R beta and gamma agonist | Clinical Trials |
|
|
| NCT05086692 | I/II | Advanced solid tumors | A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors | CA, FL, GA, MI | View Drugs | View Results |
MDNA11 | | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05382325 | I | Advanced solid tumors (inc expansion) | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors | SD, TX | View Drugs | View Results |
MK-1484 | | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04250155 | I | Advanced solid tumors (inc expansion) | A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | CA, CT, TN, VA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | XmAb24306 | interleukin-15/interleukin-15 receptor alpha complex-Fc fusion protein XmAb24306, IL15/IL15R alpha heterodimeric Fc-fusions | IL-2R/IL-15R beta and gamma agonist | Clinical Trials |
|
|